About: NSafety and Effectiveness of Azithromycin in Patients with COVID-19: an open-label randomized trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: NSafety and Effectiveness of Azithromycin in Patients with COVID-19: an open-label randomized trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	NSafety and Effectiveness of Azithromycin in Patients with COVID-19: an open-label randomized trial
Creator	Ahmadinejad, Zahra Ghiasvand, Fereshteh Golestan, Shahmari Hajiabdolbaghi, Mahboubeh Jafari, Fatemeh Jafari, Sirous Jamali, Saeidreza Khalili, Hosein Kouchak, Hamid Manafi, Navid Pirhayati, Mohammad Sadr, Sara Salehi, Mohamadreza Seifi, Arash Sekhavati, Ehsan Seyedalinaghi, Seyedahmad Siahkali, Moghadam Tabarestani, Mohammad Zendehdel, Abolfazl
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: As no specific pharmacologic treatment has been validated for use in COVID-19, we aimed to assess the effectiveness of azithromycin in these patients at a referral center in Iran. METHODS: An open-label, randomized, and controlled trial was conducted on patients with laboratory confirmed COVID-19. The 55 patients of the control group receiving hydroxychloroquine and lopinavir / ritonavir were compared with the 56 patients of the case group who in addition to the same regimen were also receiving azithromycin. Patients with prior cardiac disease were excluded from the study. Furthermore, patients from the case group were assessed for cardiac arrythmia risk based on the American college of cardiology (ACC) risk assessment for use of azithromycin and hydroxychloroquine. The main outcome measures were vital signs, SpO2 levels, duration of hospitalization, need for and length of intensive care unit (ICU) admission, mortality rates, and results of 30-day follow-up after discharge. RESULTS: Initially, there was no significant difference between the general conditions and vital signs of the two groups. The SpO2 levels at discharge were significantly higher, the respiratory rate was lower, and the duration of admission was shorter in the case group. There was no significant difference in the mortality rate between the two groups. CONCLUSION: Patients who received azithromycin in addition to the hydroxychloroquine and Kaletra regimen had a better general condition. he hydroxychloroquine-azithromycin combination may be beneficial for individuals who are known to have a very low underlying risk for cardiac arrhythmias based on the ACC criteria.
has issue date	2020-08-25(xsd:dateTime)
bibo:doi	10.1016/j.ijantimicag.2020.106143
bibo:pmid	32853672
has license	no-cc
sha1sum (hex)	d923fe3e77a5c19b8543779d3e10ab10fa51e882
schema:url	https://doi.org/10.1016/j.ijantimicag.2020.106143
resource representing a document's title	NSafety and Effectiveness of Azithromycin in Patients with COVID-19: an open-label randomized trial
has PubMed Central identifier	PMC7445147
has PubMed identifier	32853672
schema:publication	Int J Antimicrob Agents
resource representing a document's body	covid:d923fe3e77a5c19b8543779d3e10ab10fa51e882#body_text
is schema:about of	named entity 'arrhythmias' named entity 'vital signs' named entity 'confidence interval' named entity 'Lopinavir/ritonavir' named entity 'China' named entity 'ICU' named entity 'control group' named entity 'lower respiratory tract' named entity '21.4%' named entity 'hydroxychloroquine' named entity 'HIV' named entity 'headache' named entity 'Odds ratio' named entity 'Iran' named entity 'risk scoring' named entity 'clinical trial' named entity 'IBM SPSS Statistics' named entity 'monotherapy' named entity 'study protocol' named entity 'Ebola' named entity 'core body temperature' named entity 'virulence' named entity 'QTc interval' named entity 'ECG' named entity 'risk assessment' named entity 'normal distribution' named entity 'QT interval' named entity 'radiographic imaging' named entity 'macrolide antibiotic' named entity 'azithromycin' named entity 'Coronavirus infection' named entity 'evolution' named entity 'COVID-19' named entity 'statistically insignificant' named entity 'arrythmia' named entity 'pharmacokinetic' named entity 'hydroxychloroquine' named entity 'control group' named entity 'azithromycin' named entity 'epidemic' named entity 'cardiac disease' named entity 'middle east respiratory syndrome' named entity 'QTc prolongation' named entity 'hydroxychloroquine' named entity 'hydroxychloroquine' named entity 'Fever' named entity 'headache' named entity 'treatment group' named entity 'effect size' named entity 'QTc' named entity 'long-term' named entity 'COVID' named entity 'COVID-19' named entity 'Disease symptoms' named entity 'Azithromycin' named entity 'SARS-CoV-2' named entity 'respiratory distress' named entity 'COVID-19' named entity 'April 24' named entity 'lopinavir' named entity 'significant effect' named entity 'hydroxychloroquine' named entity 'China'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software